Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MLYCD | O95822 | 2/20 | 0.35 |
| ▸ | SHBG | P04278 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6585240 | 0.87 | EPHX2 (0.40) | MAOBEPHX2NR1H4NR3C1PGR | |
| SCHEMBL6582083 | 0.84 | NR3C2 (0.49) | NR3C1PGRNR3C2KMT2ALMNA | |
| SCHEMBL6587565 | 0.79 | MLYCD (0.43) | EPHX2NR1H4NR3C1PGRNR3C2 | |
| SCHEMBL6583893 | 0.79 | TET2 (0.38) | NR3C1PGRNR3C2LMNAMAPT | |
| SCHEMBL13898101 | 0.76 | NR3C2 (0.48) | NR3C1PGRNR3C2KMT2ALMNA | |
| SCHEMBL6588743 | 0.76 | NR1H4 (0.41) | NR1H4NR3C1NR3C2LMNASMN1; SMN2 | |
| SCHEMBL6583154 | 0.76 | NR3C1 (0.36) | NR3C1PGRNR3C2SMN1; SMN2GAA | |
| SCHEMBL17877682 | 0.73 | HSD11B1 (0.51) | MAOB | |
| SCHEMBL15457758 | 0.73 | MAOB (0.47) | MAOBEPHX2NR1H4KIF11KMT2A | |
| SCHEMBL27505889 | 0.72 | NR3C2 (0.41) | NR3C1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030203902-A1 | Nonsteroidal gestagens | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-30 | — | — | US | claimed |
| US-20020016365-A1 | Nonsteroidal gestagens | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-07 | — | — | US | claimed |
| US-6245804-B1 | CONTRACEPTIVES; UROGENITAL DISORDERS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-06-12 | — | — | US | claimed |
| CN-100445272-C | Non-steroidal (hetero) cyclically substd. acylanilides with mixed gestagen and androgen activity | SCHERING AG (DE) | 2008-12-24 | — | — | CN | disclosed |
| EP-0986545-B1 | NON-STEROIDAL (HETERO) CYCLICALLY SUBSTITUTED ACYLANILIDES WITH MIXED GESTAGEN AND ANDROGEN ACTIVITY | SCHERING AG (DE) | 2004-12-29 | — | — | EP | disclosed |
| US-20030203902-A1 | Nonsteroidal gestagens | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-30 | — | — | US | disclosed |
| US-6548534-B2 | Nonsteroidal gestagens | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-15 | — | — | US | disclosed |
| US-20020016365-A1 | Nonsteroidal gestagens | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-07 | — | — | US | disclosed |
| US-6344454-B1 | CONTRACEPTIVE PREPARATIONS,TREATMENT OF ENDOMETRIOSIS, GYNECOLOGICAL DISORDERS,PREMENSTRUAL SYMPTOMS, MALE BIRTH CONTROL, MALE HRT AND HORMONE THERAPY AND FOR TREATING ANDROLOGICAL DISEASE AGENTS. | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-05 | — | — | US | disclosed |
| US-6245804-B1 | CONTRACEPTIVES; UROGENITAL DISORDERS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-06-12 | — | — | US | disclosed |
| CN-1258286-A | Non-steroidal (hetero) cyclically substd. acylanilides with mixed gestagen and androgen activity | SCHERING AG (DE) | 2000-06-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016365-A1 | Nonsteroidal gestagens | NR5A1, GPER1, ESR2 | MAOB 1190/4885EPHX2 1539/4885NR1H4 49/4885 |
| US-20030203902-A1 | Nonsteroidal gestagens | GPER1, NR5A1, ESR2 | MAOB 912/4885EPHX2 1180/4885NR1H4 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.